Secondary Logo

Journal Logo

Drugs for HIV infection

Dalal, Kavitha S. PharmD; Bridgeman, Mary Barna PharmD, BCPS

doi: 10.1097/01.NURSE.0000530313.24928.ef

Kavitha S. Dalal is a critical care pharmacist at Virtua in Marlton, N.J. Mary Barna Bridgeman is a clinical associate professor at Rutgers University Ernest Mario School of Pharmacy in Piscataway, N.J.

Unless otherwise specified, the information in the preceding summaries applies to adults, not children. Consult the package insert for information about each drug's safety during pregnancy and breastfeeding. Also consult a pharmacist, the package insert, or a comprehensive drug reference for more details on precautions, drug interactions, and adverse reactions.

Can you identify these antiretroviral therapy (ART) drugs indicated to treat HIV infection? To find out, match each brand name in Section I with its generic name in Section II.

Back to Top | Article Outline

Section I

_____ 1. Genvoya (Gilead Sciences)

_____ 2. Odefsey (Gilead Sciences)

_____ 3. Prezcobix (Janssen Therapeutics)

Back to Top | Article Outline

Section II

a. elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. This combination drug consists of an HIV-1 integrase strand transfer inhibitor, a CYP3A inhibitor, and two nucleoside analog reverse transcriptase inhibitors (NRTIs). It's indicated to treat HIV-1 infection in adults and pediatric patients weighing at least 25 kg who meet certain specific clinical criteria. Before starting therapy, patients should be tested for hepatitis B virus infection. Before and during treatment, as clinically appropriate, serum creatinine, estimated creatinine clearance, urine glucose, and urine protein should be assessed in all patients. In patients with chronic kidney disease, serum phosphorus should also be assessed.

b. darunavir and cobicistat. A combination of an HIV-1 protease inhibitor and a CYP3A inhibitor, this product is indicated to treat HIV-1 infection in treatment-naive and treatment-experienced adults with no darunavir resistance-associated substitutions. Genotype testing is advised before therapy starts.

c. emtricitabine, rilpivirine, and tenofovir alafenamide. This drug is a combination of two HIV NRTIs and a nonnucleoside reverse transcriptase inhibitor, indicated as a complete regimen to treat HIV-1 infection in patients age 12 years and older as initial therapy in those with no ART treatment history and who meet specific clinical criteria. Monitor liver function tests before and during treatment for possible hepatotoxicity.

Resources available upon request.

ANSWERS: 1a, 2c, 3b

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.